HTG Molecular Diagnostics, Inc. (HTGM)
| Market Cap | 11.71M |
| Revenue (ttm) | 8.07M |
| Net Income (ttm) | -22.07M |
| Shares Out | 11.05M |
| EPS (ttm) | -2.53 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 296,395 |
| Open | 1.00 |
| Previous Close | 1.04 |
| Day's Range | 0.98 - 1.10 |
| 52-Week Range | 0.46 - 6.98 |
| Beta | 1.28 |
| Analysts | Buy |
| Price Target | 3.83 (+261.3%) |
| Earnings Date | Aug 11, 2022 |
About HTGM
HTG Molecular Diagnostics, Inc. a life sciences company, focuses on the precision medicine. The company offers instruments; consumables comprising assay kits; and software that automate sample processing and profiles various molecular targets. Its marketed molecular profiling panels include HTG Transcriptome Panel; HTG EdgeSeq precision immuno-oncology panel; HTG EdgeSeq miRNA whole-transcriptome assay; HTG EdgeSeq DLBCL cell of origin assay EU; HTG EdgeSeq DLBCL cell of origin assay; HTG EdgeSeq Oncology Biomarker Panel; HTG EdgeSeq ALKPlus as... [Read more...]
Financial Performance
In 2021, HTGM's revenue was $8.91 million, an increase of 4.19% compared to the previous year's $8.55 million. Losses were -$17.15 million, -17.85% less than in 2020.
Financial StatementsAnalyst Forecast
According to 8 analysts, the average rating for HTGM stock is "Buy." The 12-month stock price forecast is 3.83, which is an increase of 261.32% from the latest price.
News
HTG Molecular Diagnostics to Announce Q2 2022 Financial Results and Host Conference Call on Thursday, August 11
TUCSON, Ariz., Aug. 04, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profi...
HTG Molecular Diagnostics Hosting a KOL Event Addressing Drug Candidate Attrition
TUCSON, Ariz., July 19, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profi...
REV, CSSE: The Top 5 Short Squeeze Stocks to Watch This Week
Short squeeze stocks are still hot among retail traders and we're helping them out with a list of companies to watch this week! The post REV, CSSE: The Top 5 Short Squeeze Stocks to Watch This Week appe...
HTG Molecular Diagnostics Announces Amendment to Senior Loan Facility
TUCSON, Ariz., July 18, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profi...
HTG Releases Second Whitepaper for its Transcriptome-Informed Approach to Drug Discovery
TUCSON, Ariz., July 06, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profi...
Publication Highlights Potential Clinical Applications of the HTG Transcriptome Panel in Bladder Cancer
TUCSON, Ariz., June 29, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profi...
HTG to Sponsor Keynote Presentation Featuring Customer Use of its HTG EdgeSeq Technology in Clinical Trials
TUCSON, Ariz., June 08, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profi...
HTG Technology Featured in Multiple Scientific Abstracts Highlighting Novel Applications in Precision Medicine at ASC...
TUCSON, Ariz., June 06, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profi...
HTG Molecular Diagnostics to Participate in the H.C. Wainwright Global Investment Conference
TUCSON, Ariz., May 17, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profil...
HTG Molecular Diagnostics, Inc. (HTGM) Reports Q1 Loss, Lags Revenue Estimates
HTG Molecular Diagnostics, Inc. (HTGM) delivered earnings and revenue surprises of -14.08% and 15.43%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for th...
HTG Molecular Diagnostics Reports First Quarter 2022 Results
Call scheduled for today, May 12, at 4:30 pm ET Call scheduled for today, May 12, at 4:30 pm ET
HTG Expands Therapeutics Team
Christina M. Carruthers, Ph.D. Joins as Vice President of Target Strategy and Early Development Christina M. Carruthers, Ph.D. Joins as Vice President of Target Strategy and Early Development
HTG Expands Features of Proprietary HTG EdgeSeq Technology
New Sample Preparation Harmonization Designed to Enable miRNA and mRNA Profiling Without the Need for Additional Sample New Sample Preparation Harmonization Designed to Enable miRNA and mRNA Profiling W...
HTG Releases Proof-of-Approach Whitepaper Establishing Utility of Transcriptome-Informed Approach to Drug Discovery
TUCSON, Ariz., March 31, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide prof...
HTG Molecular Diagnostics Reports Full Year 2021 Results
Call scheduled for today, March 29, at 4:30 pm ET Call scheduled for today, March 29, at 4:30 pm ET
HTG Molecular Diagnostics Announces $7.5 Million Private Placement
TUCSON, Ariz., March 18, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced that it has...
HTG Names Renowned RNA Expert Dr. Robert Spitale to Therapeutics Scientific Advisory Board
TUCSON, Ariz., Feb. 03, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profi...
HTG Appoints Biopharmaceutical Industry Veteran Christopher Kiritsy to its Board of Directors
Brings Significant Operational Experience in Building Therapeutic Drug Development Businesses Brings Significant Operational Experience in Building Therapeutic Drug Development Businesses
HTG Molecular Diagnostics Announces Certain Preliminary 2021 Unaudited Financial Results
Preliminary full year 2021 unaudited revenue of $8.9 million
HTG Completes HTP Product Next-Phase Development Milestone
Expands Potential Market and Study Opportunities for HTG Transcriptome Panel Expands Potential Market and Study Opportunities for HTG Transcriptome Panel
HTG Expands Therapeutics Scientific Advisory Board With Addition of Dr. Jerald Radich
Renowned Physician-Scientist Brings Significant Expertise as a Pioneer in the Fields of Leukemia Research and Molecular Genetics Renowned Physician-Scientist Brings Significant Expertise as a Pioneer in...
HTG and Icahn School of Medicine at Mount Sinai Announce Bladder Cancer Research Collaboration
HTG's Innovative Transcriptome Panel Technology to be Leveraged in Retrospective Studies HTG's Innovative Transcriptome Panel Technology to be Leveraged in Retrospective Studies
HTG Molecular Diagnostics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
TUCSON, Ariz., Nov. 15, 2021 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profi...
Preview: HTG Molecular Diagnostics's Earnings
HTG Molecular Diagnostics (NASDAQ:HTGM) is set to give its latest quarterly earnings report on Wednesday, 2021-11-10. Here's what investors need to know before the announcement.
HTG Molecular Diagnostics to Present at H.C. Wainwright's 23rd Annual Global Investment Conference
TUCSON, Ariz., Sept. 08, 2021 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced that compan...